{"id":"W3016549455","doi":"10.1158/1078-0432.ccr-19-3979","title":"FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Canada","funders":"","keywords":"Lenvatinib; Pembrolizumab; Medicine; Endometrial cancer; Internal medicine; Oncology; Expanded access; Clinical trial; Cancer; Thyroid cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002336587,0.0002834945,0.001219187,0.0002765622,0.0001767483,0.00006785509,0.0005029151,0.0002229904,0.001258716],"category_scores_gemma":[0.01157332,0.0002121466,0.0005127707,0.003086452,0.0003868821,0.0001316415,0.0003037755,0.001033657,0.00008003221],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007787195,"about_ca_system_score_gemma":0.004187674,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000580779,"about_ca_topic_score_gemma":0.00006990241,"domain_scores_codex":[0.9949381,0.0006379148,0.001121988,0.001006692,0.00160018,0.0006951495],"domain_scores_gemma":[0.9936962,0.003271105,0.0002155522,0.0003912895,0.001815216,0.000610644],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.1450994,0.002026426,0.03264307,0.007310565,0.00306194,0.0002663601,0.0006059397,0.00001150653,0.0003415062,0.002356915,0.6053843,0.200892],"study_design_scores_gemma":[0.09859522,0.0132112,0.007260734,0.002048718,0.0007455532,0.00001476163,0.0006152079,0.0005921701,0.0007954455,0.0005428038,0.8749512,0.0006269566],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.2361732,0.2197235,0.001384295,0.4087975,0.008625078,0.05257495,0.00551946,0.000617359,0.06658466],"genre_scores_gemma":[0.8855637,0.06616846,0.001867362,0.01953686,0.01345048,0.007050186,0.0008158464,0.0001689703,0.005378124],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.6493905,"threshold_uncertainty_score":0.9996543,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.4459423475339773,"score_gpt":0.5660444547712383,"score_spread":0.1201021072372611,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}